Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas - PubMed (original) (raw)
. 2012 Jul:19 Suppl 3:S347-54.
doi: 10.1245/s10434-011-1799-8. Epub 2011 May 24.
Masashi Kobayashi, Masashi Ishikawa, Ryutaro Kikuchi, Ei Nakayama, Tsuyoshi Takahashi, Toshi Menju, Kazumasa Takenaka, Ryo Miyahara, Cheng-Long Huang, Kenichi Okubo, Toru Bando, Hiroshi Date
Affiliations
- PMID: 21607772
- DOI: 10.1245/s10434-011-1799-8
Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas
Makoto Sonobe et al. Ann Surg Oncol. 2012 Jul.
Abstract
Background: Oncogenic gene mutations observed in lung adenocarcinomas, such as epidermal growth factor receptor (EGFR) and KRAS, have some predictive value for chemotherapeutic drugs or EGFR-tyrosine kinase inhibitors. However, the influence of these gene alterations on patients' prognosis remains controversial.
Methods: We retrospectively analyzed the tumors of 180 patients with completely resected pathological stage I-III lung adenocarcinoma which harbored either KRAS codon 12 mutation or EGFR gene mutations within exons 18-21 to investigate the impact of these gene mutations on the patients' survival. Gene mutations were detected by established methods.
Results: Of 180 patients, 32 had KRAS codon 12 mutations (KRAS group), 148 had EGFR mutations within exon 18-21 (EGFR group). Pathological stage and operation mode were independent factors for disease-free survival. However, the EGFR group had better overall survival than the KRAS group (P = 0.0271). Cox proportional hazard model revealed pathological stage (P = 0.0001) and presence of EGFR gene mutations (P = 0.0408) were independent factors for overall survival. In survival after tumor recurrence, the EGFR group had a better median survival time (46.7 months) after recurrence than the KRAS group (26.0 months).
Conclusions: In patients with completely resected lung adenocarcinomas, KRAS and EGFR gene mutation status of tumors was not associated with disease-free survival. However, the presence of an EGFR gene mutation boded well for the patient's overall survival, and thus patients with EGFR mutations have a better prognosis than those with KRAS mutations.
Similar articles
- Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F. Ragusa M, et al. Am J Clin Oncol. 2014 Aug;37(4):343-9. doi: 10.1097/COC.0b013e31827a7e7a. Am J Clin Oncol. 2014. PMID: 23357969 - KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, Chen ZH, Yan HH, Chen ZY, Huang ZM, Zhang XC, Nie Q, Wu YL. Guan JL, et al. Ann Surg Oncol. 2013 Apr;20(4):1381-8. doi: 10.1245/s10434-012-2754-z. Epub 2012 Dec 4. Ann Surg Oncol. 2013. PMID: 23208128 Clinical Trial. - Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Kosaka T, et al. J Thorac Oncol. 2009 Jan;4(1):22-9. doi: 10.1097/JTO.0b013e3181914111. J Thorac Oncol. 2009. PMID: 19096302 Clinical Trial. - KRAS mutations in lung cancer.
Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. Karachaliou N, et al. Clin Lung Cancer. 2013 May;14(3):205-14. doi: 10.1016/j.cllc.2012.09.007. Epub 2012 Nov 1. Clin Lung Cancer. 2013. PMID: 23122493 Review. - KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
Guibert N, Ilie M, Long E, Hofman V, Bouhlel L, Brest P, Mograbi B, Marquette CH, Didier A, Mazieres J, Hofman P. Guibert N, et al. Curr Mol Med. 2015;15(5):418-32. doi: 10.2174/1566524015666150505161412. Curr Mol Med. 2015. PMID: 25941815 Review.
Cited by
- Prognosis of metastasis based on age and serum analytes after follow-up of non-metastatic lung cancer patients.
Balla MMS, Patwardhan S, Melwani PK, Purwar P, Kumar A, Pramesh CS, Laskar S, Pandey BN. Balla MMS, et al. Transl Oncol. 2021 Jan;14(1):100933. doi: 10.1016/j.tranon.2020.100933. Epub 2020 Nov 11. Transl Oncol. 2021. PMID: 33188981 Free PMC article. - Clinicopathological factors associated with sentinel lymph node detection in non-small-cell lung cancer.
Wollbrett C, Seitlinger J, Stasiak F, Piccoli J, Streit A, Siat J, Gauchotte G, Renaud S. Wollbrett C, et al. J Cardiothorac Surg. 2024 Mar 19;19(1):145. doi: 10.1186/s13019-024-02632-y. J Cardiothorac Surg. 2024. PMID: 38504315 Free PMC article. - Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
Hyung J, Yoon H, Choi CM, Yoon S, Lee DH, Kim SW, Kim HR, Kim SS, Song SY, Lee JC. Hyung J, et al. J Cancer Res Clin Oncol. 2023 Jul;149(8):4243-4251. doi: 10.1007/s00432-022-04287-5. Epub 2022 Sep 5. J Cancer Res Clin Oncol. 2023. PMID: 36064984 - Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y, Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T, Chen F, Omasa M, Date H. Yokoyama Y, et al. Int J Clin Oncol. 2015 Dec;20(6):1122-9. doi: 10.1007/s10147-015-0838-z. Epub 2015 May 8. Int J Clin Oncol. 2015. PMID: 25953679 - The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
Honda T, Seto K, Endo S, Takemoto A, Tanimoto K, Kobayashi M, Kitano M, Sakakibara R, Mitsumura T, Ishibashi H, Inazawa J, Tanaka T, Miyazaki Y, Okubo K. Honda T, et al. Cancer Med. 2023 Oct;12(19):19406-19413. doi: 10.1002/cam4.6535. Epub 2023 Sep 15. Cancer Med. 2023. PMID: 37712717 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous